Regulus Therapeutics (RGLS) Plunges on FDA Decision; Knight Therapeutics Eyeing Potential In Protalix Biotherapeutics (PLX)


Shares of Regulus Therapeutics Inc. (Nasdaq:RGLS) plummeted more than 20% to touch a new 52-week low in the extended session Friday after the company said that the U.S. Food and Drug Administration (FDA) maintained the clinical hold – placed by the government agency in June last year – on its hepatitis C virus drug, RG-101.

RGLS stock closed at $2.25 with a total volume of 311,403 shares traded during the day.

Regulus Therapeutics,which focuses on the discovery and development of drugs that target RNAs to treat a range of diseases, has 52.92M shares outstanding. At close on Friday, the biopharmaceutical company had a market capitalization of $119.08M and RGLS stock one-year range was between $2.12 and $8.90 per share.



Protalix Biotherapeutics Inc. (NYSEMKT:PLX) stock climbed 11.71% (or +$0.065) to $0.62 on Friday’s trading session after Canada-based Knight Therapeutics Inc. (TSE:GUD) said it bought – for investment purposes – 6.2 million shares of the biopharmaceutical company at an average cost of $0.57 each.

Protalix Biotherapeutic, which focuses on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, has 123.87M shares outstanding, market capitalization (intraday) of $76.8M and PLX stock 52-week range is from $0.26 to $0.96 per share.


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at